June 26, 2025

Intestinal barrier in inflammatory bowel disease: Mechanisms and treatment

June 26, 2025 / Clinical Practice / InnovateMed Author / IBD

Peer-Reviewed Publication Xia & He Publishing Inc. FacebookXLinkedInWeChatBlueskyMessageWhatsAppEmail image: mTOR, mammalian target of rapamycin; p70S6K, The 70kDa ribosomal S6 kinase 1; NLRP3, NOD-like receptor thermal protein domain associated protein 3; ASC, apoptosis-associated speck-like protein containing a CARD; caspase, cysteinyl aspartate specific proteinase; IL-1β, Interleukin-1beta. view more Credit: Yan Chen Inflammatory bowel disease (IBD), encompassing ulcerative […]

Intestinal barrier in inflammatory bowel disease: Mechanisms and treatment Read More »

Long-term use of rifaximin in cirrhotic patients with hepatic encephalopathy

June 26, 2025 / Clinical Practice / InnovateMed Author / hepatic encephalopathy

Peer-Reviewed Publication Xia & He Publishing Inc. FacebookXLinkedInWeChatBlueskyMessageWhatsAppEmail image: Rifaximin improves the gut microenvironment by reducing the abundance of harmful bacteria while increasing probiotic bacteria. It inhibits the translocation of bacteria from the mouth to the intestine and decreases the population of mucus-degrading species and ammonia-producing bacteria within the gut. By strengthening epithelial tight junctions,

Long-term use of rifaximin in cirrhotic patients with hepatic encephalopathy Read More »